Abstract:Highly specific and efficient drugs have been developed during the last two decades to treat non-communicable chronic inflammatory skin diseases (ncISD). Due to their specificity, these drugs are asking for precise diagnostic measures to attribute the most efficient treatment to each patient. Diagnosis, however, is complicated by the complex pathogenesis of ncISD and their clinical and histological overlap. Especially, precise diagnosis of psoriasis and eczema is difficult in special cases and molecular diagnostic tools need to be developed to support gold standard diagnosis of patients. In this line, we have developed a real-time based molecular classifier to distinguish psoriasis from eczema in RNA-later fixed skin samples. However, this type of skin sample is not regularly used in routine diagnostics. Therefore, we evaluated if the combination of NOS2 and CCL27 expression in lesional skin can be transferred to formalin-fixed paraffin embedded (FFPE) tissue. We present a FFPE-based molecular classifier (MC) that determines the probability for psoriasis with a specificity and sensitivity of 100% and 92%, respectively, and an area under the curve (AUC) of 0.97 delivering comparable results to the RNA-later based MC. The probability for psoriasis as well as the PCR result of NOS2 expression correlated positive with disease hallmarks of psoriasis and negative with eczema hallmarks. This tool now offers broad usage in pathology laboratories and can support diagnostic decision making on a molecular level.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThis work was supported by the Medical Valley Award.### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the ethical committee of the Klinikum rechts der Isar, Technical University Munich (project number 2773/10 and 515/17)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenerated data and codes can be provided upon request

Occupational palmoplantar psoriasis: a clinical case series with consideration of the S1 guidelines on expert medical assessments of occupational psoriasis

Medico-legal evaluation of occupational skin diseases and occupational skin cancer

Palmoplantar Psoriasis: Epidemiological and Clinical Features and Impact on Quality of Life

Gene Expression Based Molecular Test Proves Clinical Validity As Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin Fixed and Paraffin Embedded Tissue

Documentation of psoriasis in routine care – expert consensus on a German data set

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

A Case of Palmoplantar Psoriasis treated by Individualised Homoeopathic Treatment: A Case Report

[Occupational skin cancer : Prevention and recommendations for UV protection as part of the treatment approved by the public statutory employers' liability insurance]

Patch testing in occupational dermatology: Practical aspects in relation to the conditions in Germany

The Hidden Costs of Psoriasis: A Population-Based Study Evaluating How Psoriasis Severity Impacts Work Absenteeism

[Individual prevention of occupational contact dermatitis: protective gloves and skin protection recommendations as part of the patient management scheme by the public statutory employers' liability insurance]

Updates on Psoriasis in Special Areas

[Skin cancer as occupational disease]

The European Status Quo in legal recognition and patient-care services of occupational skin cancer

Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects

Population-based incidence of psoriasis vulgaris in Germany: analysis of national statutory insurance data from 65 million population

Psoriatic arthritis. Clinical guidelines for diagnosis and treatment

Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

Assessing work-related productivity loss and indirect costs of psoriasis across six countries

Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group